Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$29.66M$29.66Mderived+4,249.6% vs Q4 2023 Net Income-$74.45M-$74.45MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$25,849,000+4,919.2% Operating Incomederived-$59,417,000N/M Operating Cash Flowderived-$63,456,000N/M Free Cash Flowderived-$63,461,000N/M Margins · derivedGross margin87.1%+11.6 pt vs Q4 2023
Operating margin-200.3%+10045.3 pt vs Q4 2023
Net margin-251.0%+11416.2 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 6, 2025 · 65 d after period end